Vulvovaginal
candidiasis (VVC) is one of the most frequent problems facing women and their
healthcare professionals (HCP). It is difficult for providers to understand the
prevalence of VVC because effective over the counter treatments(OTC),
are available. It is expected that there are a great many more episodes of VVC
in our patient population, as the frequency of self-treatment, success and satisfaction for those that use OTC products prior to seeing a
women’s health care provider is unknown. In this study; healthcare providers were
given OTC miconazole/tioconazole units for free distribution to patients for
whom they diagnosed VVC by exam in their offices. Surveys for both HCP and
patients were also distributed to determine the initial or recurrent nature of
their symptoms and their satisfaction with their treatments. 1265 OBGYNs and 1821
NP/CNM/PAs reported on over 19,000 patients
receiving a single complete treatment.Among HCPs, treatment efficacy was the primary
reason for recommending miconazole/tioconazole.
However, rapid onset of symptom relief, safety vs. fluconazole, patient preference
for the less messy ovule, avoidance with drugs metabolized by the liver, and
resistance to, or failure on, fluconazole were additional reasons noted for
topical preference.Overall, patient satisfaction (n=
References
[1]
Mintz, J.D. and Martens, M.G. (2013) Prevalence of Non-Albicans Candida Infections in Women with Recurrent Vulvovaginal Symptomatology. Advances in Infectious Diseases, 3, 238-242. https://doi.org/10.4236/aid.2013.34035
[2]
Centers for Disease Control and Prevention, Sexually Transmitted Diseases Treatment Guidelines (2015) http://www.cdc.gov/std/tg2015/tg-2015-print.pdf
[3]
Sobel, J.D., Wiesenfeld, H.C., Martens, M.G., et al. (2004) Maintenance Fluconazole Therapy for Recurrent Vulvovaginal Candidiasis. The New England Journal of Medicine, 351, 876-883. https://doi.org/10.1056/NEJMoa033114
[4]
van Heusden, A.M., Merkus, H.M., Corbeij, H.S., et al. (1990) Single-Dose Oral Fluconazole versus Single-Dose Topical Miconazole for the Treatment of Acute Vulvovaginal Candidosis. Acta Obstetricia et Gynecologica Scandinavica, 69, 417-422. https://doi.org/10.3109/00016349009013305
[5]
Bruggemann, R.J., Alffenaar, J.W., Blijlevens, N.M., et al. (2009) Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents. Clinical Infectious Diseases, 49, 1441-1458.
https://doi.org/10.1086/598327
[6]
Sinofsky, F.E. and Pasquale, S.A. (1998) The Effect of Fluconazole on Circulating Ethinyl Estradiol Levels in Women Taking Oral Contraceptives. American Journal of Obstetrics & Gynecology, 178, 300-304.
https://doi.org/10.1016/S0002-9378(98)80016-1
[7]
Willams, N.S., Phillips, N. and Bachmann, G. (2015) Oral Compared with Local Antifungal Treatment of Yeast Infection: Comparison of Time to Symptomatic Relief. Obstetrics & Gynecology, 125, 11S.
https://doi.org/10.1097/01.AOG.0000463549.01588.2b
[8]
Marchaim, D., Lemanek, L., Bheemreddy, S., Kaye, K.S. and Sobel, J.D. (2012) Fluconazole-Resistent Candida albicans Vulvovaginitis. Obstetrics and Gynecology, 120, 1407-1414. https://doi.org/10.1097/AOG.0b013e31827307b2
[9]
Shabid, Z. and Sobel, J.D. (2009) Reduced Fluconazole Susceptibility of Candida albicans Isolates in Women with Recurrent Vulvovaginal Candidiasis: Effects of Long-Term Fluconazole Therapy. Diagnostic Microbiology and Infectious Disease, 64, 354-356. https://doi.org/10.1016/j.diagmicrobio.2009.03.021
[10]
Vazquez, J.A., Peng, G., Sobel, J.D., et al. (2001) Evolution of Antifungal Susceptibility among Candida Species Isolates Recovered from Human Immunodeficiency Virus-Infected Women Receiving Fluconazole Prophylaxis. Clinical Infectious Diseases, 33, 1069-1075. https://doi.org/10.1086/322641
